OBJECTIVE: Studying chemotherapy-induced gene expression changes in vivo, which could provide insights into mechanisms of chemotherapy resistance. METHODS: We analyzed and compared tumor gene expression changes of about 38 500 genes before and 3 weeks after doxorubicin or docetaxel treatment in 47 breast cancer patients. RESULTS: By using the median expression level of each probe set as the parameter, less than 5% of genes were upregulated or downregulated by more than 50% after treatment with either drug. Doxorubicin and docetaxel concordantly induced 251 genes predominantly involved in protein and macromolecule metabolism (upregulated), and cell cycle and DNA/RNA metabolism (downregulated). Doxorubicin treatment resulted in coregulation of a cluster of 345 probe sets involved in focal adhesion, Jak-Stat signaling pathway, cell adhesion molecules, and natural killer cell mediated cytotoxicity, whereas docetaxel treatment resulted in coregulation of a cluster of 448 probe sets involved in focal adhesion, neurodegenerative disorders, sphingolipid metabolism, and cell cycle. Tumors that were intrinsically sensitive or resistant to doxorubicin or docetaxel evoked distinct gene expression changes in response to the drug; doxorubicin-resistant tumors upregulated genes that were enriched for ErbB signaling, ubiquitin-mediated proteolysis, TGF-beta signaling, and MAP-kinase signaling pathways, whereas docetaxel-resistant tumors upregulated genes that were enriched for focal adhesion and regulation of actin cytoskeleton. The drug-specific tumor gene expression changes were validated in independent in-vitro and in-vivo datasets. CONCLUSION: Gene expression alterations of breast cancer were specific to doxorubicin and docetaxel treatment, and yielded mechanistic insights into resistance to either drug. Gene expression analysis provides more global perspectives on resistance pathways that could be exploited for therapeutic selection.
RCT Entities:
OBJECTIVE: Studying chemotherapy-induced gene expression changes in vivo, which could provide insights into mechanisms of chemotherapy resistance. METHODS: We analyzed and compared tumor gene expression changes of about 38 500 genes before and 3 weeks after doxorubicin or docetaxel treatment in 47 breast cancerpatients. RESULTS: By using the median expression level of each probe set as the parameter, less than 5% of genes were upregulated or downregulated by more than 50% after treatment with either drug. Doxorubicin and docetaxel concordantly induced 251 genes predominantly involved in protein and macromolecule metabolism (upregulated), and cell cycle and DNA/RNA metabolism (downregulated). Doxorubicin treatment resulted in coregulation of a cluster of 345 probe sets involved in focal adhesion, Jak-Stat signaling pathway, cell adhesion molecules, and natural killer cell mediated cytotoxicity, whereas docetaxel treatment resulted in coregulation of a cluster of 448 probe sets involved in focal adhesion, neurodegenerative disorders, sphingolipid metabolism, and cell cycle. Tumors that were intrinsically sensitive or resistant to doxorubicin or docetaxel evoked distinct gene expression changes in response to the drug; doxorubicin-resistant tumors upregulated genes that were enriched for ErbB signaling, ubiquitin-mediated proteolysis, TGF-beta signaling, and MAP-kinase signaling pathways, whereas docetaxel-resistant tumors upregulated genes that were enriched for focal adhesion and regulation of actin cytoskeleton. The drug-specific tumor gene expression changes were validated in independent in-vitro and in-vivo datasets. CONCLUSION: Gene expression alterations of breast cancer were specific to doxorubicin and docetaxel treatment, and yielded mechanistic insights into resistance to either drug. Gene expression analysis provides more global perspectives on resistance pathways that could be exploited for therapeutic selection.
Authors: Yang Yu; Yujun Wang; Xiubao Ren; Akihiro Tsuyada; Arthur Li; Liguang James Liu; Shizhen Emily Wang Journal: Mol Cancer Res Date: 2010-10-14 Impact factor: 5.852
Authors: Emilie Millerot-Serrurot; Marie Guilbert; Nicolas Fourré; Wojciech Witkowski; Georges Said; Laurence Van Gulick; Christine Terryn; Jean-Marie Zahm; Roselyne Garnotel; Pierre Jeannesson Journal: Cancer Cell Int Date: 2010-08-13 Impact factor: 5.722
Authors: Renata Duchnowska; Jacek Jassem; Chirayu Pankaj Goswami; Murat Dundar; Yesim Gökmen-Polar; Lang Li; Stephan Woditschka; Wojciech Biernat; Katarzyna Sosińska-Mielcarek; Bogumiła Czartoryska-Arłukowicz; Barbara Radecka; Zorica Tomasevic; Piotr Stępniak; Konrad Wojdan; George W Sledge; Patricia S Steeg; Sunil Badve Journal: J Neurooncol Date: 2015-01-06 Impact factor: 4.130
Authors: Sing-Huang Tan; Nur Sabrina Sapari; Hui Miao; Mikael Hartman; Marie Loh; Wee-Joo Chng; Philip Iau; Shaik Ahmad Buhari; Richie Soong; Soo-Chin Lee Journal: PLoS One Date: 2015-12-02 Impact factor: 3.240